Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Immix Biopharma completed a $5M ATM equity offering, selling 2,263,868 shares. Funds will support IMX-110 clinical trials and general corporate purposes. The company focuses on CAR-T cell therapies and TSTx for oncology and immuno-dysregulated diseases, with NXC-201 as a leading outpatient CAR-T therapy.
Reference News
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Immix Biopharma completed a $5M ATM equity offering, selling 2,263,868 shares. Funds will support IMX-110 clinical trials and general corporate purposes. The company focuses on CAR-T cell therapies and TSTx for oncology and immuno-dysregulated diseases, with NXC-201 as a leading outpatient CAR-T therapy.